Automation will be key to improving efficiency and mitigating risk during the complex process of cell therapy production and delivery.
Rolf Ehrhardt
Advertisement
Rolf Ehrhardt, MD, PhD is CEO of MedCision.
Articles by Rolf Ehrhardt
In this article, MedCision executive discusses cell therapies.
Advertisement
Latest Updated Articles
- The Success of Cell Therapies Will Depend on Automation
Published: July 14th 2017 | Updated:
The Success of Cell Therapies Will Depend on AutomationPublished: October 1st 2017 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV
2
Proactive Planning is Key to Mitigating Study Rescue
3
ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results
4
FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
